The secretion of glucocorticoids (GCs) represents the final step in a
neuroendocrine cascade beginning within the CNS. Somatic and
psychogenic stressors, as well as circadian drive, initiate the cascade
by releasing hypothalamic ACTH-secretagogues. A major advance in recent
years in the recognition that CRF is only the principal of numerous
secretagogues, icnluding vasopressin (AVP), oxytocin (OT) and
catecholamines. Superimposed upon this complex regulatory system are
the negative feedback actions of GCs, acting at both adenohypophysial
and CNS sites.
The demonstration of dexamethasone (DEX) resistance and hypercortisolism
in depression and Alzheimer's disease (AD) was exciting for biological
psychiatry, for these neuroendocrine abnormalities testifed to the
biological underpinnings of such disorders. Furthermore, that only some
patients had adrenocortical abnormalities gave credence to ideas of
heterogeneity to affective disorders, and promised a diagnostic tool for
sub-typing depressive individuals; however, some of this optimism has
waned. While the endocrine abnormalities of DEX resistance and
hypercortisolism still testify to the biological reality of affective
disorders and of AD, it is not clear yet precisely what that biological
reality is. Using various rat models of glucocorticoid hypersecretion
and feedback resistance, this proposal addresses the broad issue:
What are the mechanisms by which feedback regulation of the
adrenocortical axis can fail at the CNS level?
Knowledge concerning the anatomical locus of the defect underlying
hypersecretion is slowly accumulating and implicate a CNS site of
dysfunction. Two particularly interesting regions in this regard are
the hippocampus and hypothalamus. We will focus our studies on the
putative role of these structures of GC-mediated feedback inhibition of
ACTH-secretagogue release, and attendant dysregulatory syndromes
resulting from disruption of these structures. Specifically, we will
investigate: (1) which ACTH-secretagogues are hypersecreted following
destruction of the hippocampus or fornix, (2) the relationship between
hippocampal or hypothalamic corticosteroid receptor occupancy and
hypophysiotropic factor release, and (3) the nature of alterations in
ACTH-secretagogue profile following up- or down-regulation of
hippocampal or hypothalamic corticosteroid receptors.
No Sub Projects information available for 7R01MH045216-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7R01MH045216-04
Patents
No Patents information available for 7R01MH045216-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7R01MH045216-04
Clinical Studies
No Clinical Studies information available for 7R01MH045216-04
News and More
Related News Releases
No news release information available for 7R01MH045216-04
History
No Historical information available for 7R01MH045216-04
Similar Projects
No Similar Projects information available for 7R01MH045216-04